Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Star
11180.5000 2.50 (0.02%)
NSE Nov 20, 2026 15:31 PM
Volume: 404.8K
 

11180.50
0.02%
ICICI Securities Limited
Divi’s Laboratories’ (Divi’s) Q1FY25 result was sub-par. Revenue traction was driven by custom synthesis (CS) (up ~46% YoY), while generics grew 1.5% YoY due to double-digit price erosion in key products like Naproxen, Gabapentin and Dexamethasone.
Divi's Laboratories has gained 62.20% in the last 6 Months
More from Divi's Laboratories Ltd.
Recommended